Non-interventional Study of the Austrian Headache Society: Monoclonal CGRP Antibodies for Migraine Prevention a Nationwide Real Life Study
Status: Recruiting
Location: See all (3) locations...
Intervention Type: Drug
Study Type: Observational
SUMMARY
The present non-interventional study on migraine prevention with monoclonal CGRP antibodies adresses questions concering safety, swichting from one CGRP mab to another, efficacy on auras in the real world setting.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
View:
• episodic or chronic migraine with or without aura
• erenumab, fremanezumab or galcanezumab is prescribed as a standard of care treatment by treating physician Eptinezumab may be included as soon as available in Austria.
Locations
Other Locations
Austria
Medical University Innsbruck
RECRUITING
Innsbruck
Clinic Hietzing
RECRUITING
Vienna
Medizinische Universität Wien
RECRUITING
Vienna
Contact Information
Primary
Franz Riederer, Prof
franz.riederer@uzh.ch
+436803279153
Backup
Karin Zebenholzer, Prof
karin.zebenholzer@meduniwien.ac.at
+43140400
Time Frame
Start Date: 2022-10-01
Estimated Completion Date: 2025-12-01
Participants
Target number of participants: 1500
Treatments
Erenumab
Patients will be treated with this drug within standard of care treatment
Galcanezumab
Patients will be treated with this drug within standard of care treatment
Fremanezumab
Patients will be treated with this drug within standard of care treatment
Related Therapeutic Areas
Sponsors
Collaborators: Medical University Innsbruck, Medical University of Vienna, Austrian Headache Society
Leads: Austrian Migraine Registry Collaboration